"“We look forward to efficient execution of this important trial for our psoriasis program. Having partnered with one of the premier CROs in the Dermatology therapy area for this study, I am confident that we will be able to assess interim and final study results in a timely fashion,” said Jane Harness, Cellceutix VP, Clinical Sciences and Portfolio Management."
https://globenewswire.com/news-release/2016/1...iasis.html
https://globenewswire.com/news-release/2016/1...iasis.html